Routine assessment and monitoring of cognitive functions should be embedded in MS care to detect relapse-related changes and progressive decline. Identifying fluid and MRI biomarkers of cognitive dysfunction may help individuate novel targets and specific treatments.
Meo et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: